Breast Cancer News

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki improved outcomes compared with capecitabine-based regimens as third-line treatment for certain patients with HER2-positive metastatic breast cancer, according to study findings.

SAN ANTONIO — The benefit of adding abemaciclib to adjuvant endocrine therapy for certain patients with high-risk breast cancer deepened with time, according to randomized phase 3 results presented at San Antonio Breast Cancer Symposium.

Adetunji T. Toriola, MD, PhD, MPH, will receive the AACR Outstanding Investigator Award for Breast Cancer Research at this year’s San Antonio Breast Cancer Symposium.

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki induced encouraging response rates among certain patients with early breast cancer, according to findings presented at San Antonio Breast Cancer Symposium.

Charles M. Perou, PhD, received the 2022 AACR Distinguished Lectureship in Breast Cancer Research at this year’s San Antonio Breast Cancer Symposium.

SAN ANTONIO — A genomic assay identified risk for distant recurrence among certain premenopausal women with hormone receptor-positive, early-stage breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — First-line ribociclib plus endocrine therapy appeared associated with longer PFS and fewer adverse events than combination chemotherapy among certain patients with advanced breast cancer, according to study results.

SAN ANTONIO — Levels of a prognostic biomarker for distant metastatic recurrence varied by race among a subset of women who received neoadjuvant chemotherapy, according to study results presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — Outcomes among women with breast cancer who have similar 21-gene recurrence scores may vary by race, according to study results presented at San Antonio Breast Cancer Symposium.

Jeffrey M. Rosen, PhD, will receive the William L. McGuire Memorial Lecture Award at this year’s San Antonio Breast Cancer Symposium, scheduled for Dec. 6-10.